Management of tics and Tourette's disorder: An update

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 11, 2010, Pages 1813-1822

  Bestha, Durga Prasad ^a   Jeevarakshagan, Shamala ^a   Madaan, Vishal ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alpha 2 agonists; Atypical antipsychotics; Habit reversal; Tourette's syndrome

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIANDROGEN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BOTULINUM TOXIN; CLONIDINE; DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; GLUTAMATE RECEPTOR AGONIST; GUANFACINE; HALOPERIDOL; KETANSERIN; LEVODOPA; MECAMYLAMINE; MEMANTINE; NEUROLEPTIC AGENT; NICOTINIC AGENT; OLANZAPINE; ONDANSETRON; PERGOLIDE; PIMOZIDE; PRAMIPEXOLE; QUETIAPINE; RILUZOLE; RISPERIDONE; ROPINIROLE; TETRABENAZINE; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HABIT REVERSAL TRAINING; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; METABOLIC SYNDROME X; MOOD DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PSYCHOSOCIAL CARE; QT PROLONGATION; REVIEW; SEDATION; SIDE EFFECT; SYNCOPE; TARDIVE DYSKINESIA; TIC; TRAINING; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT INDICATION; TREATMENT OUTCOME; WEIGHT GAIN; TICS; TOURETTE SYNDROME;

HUMANS; TICS; TOURETTE SYNDROME;

EID: 77954772901     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.486402     Document Type: Review

References (86)

1. Diagnostic and statistical manual of mental disorders IV text revision, American Psychiatric Association; 2000
2. Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 2009;67(6):475-483
3. Khalifa N, von Knorring AL. Prevalence of tic disorders and Tourette syndrome in a Swedish school population. Dev Med Child Neurol 2003;45:315-319
4. Khalifa N, von Knorring AL. Psychopathology in a Swedish population of school children with tic disorders. J Am Acad Child Adolesc Psychiatry 2006;45:1346-1353
5. Bloch MH, Peterson BS, Scahill L, et al. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med 2006;160:65-119
6. Sukhodolsky DG, Scahill L, Zhang H, et al. Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry 2003;42:98-105
7. Leckman JF, Grice DE, Barr LC, et al. Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety 1994;1:208-215
8. Gaze C, Kepley HO, Walkup JT. Co-occurring psychiatric disorders in children and adolescents with Tourette syndrome. J Child Neurol 2006;21(8):, 657-664
9. Leckman JF, Zhang H, Vitale A, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998;102(1 Pt 1):l4-9
10. Lin H, Katsovitch L, Ghebremichael M, et al. Psychosocial stress predicts future symptom severities in children and adolescents with Tourette syndrome and/ or obsessive-compulsive disorder. J Child Psychol Psychiatry 2007;48(2):157-166
11. Woods DW, Watson TS, Wolfe E, et al. Analyzing the influence of tic related talk on vocal and motor tics in children with Tourette's syndrome. J Appl Behav Anal 2001;34(3):353-356
12. Silvestri R, De Domenico P, Di Rosa AE, et al. The effect of nocturnal physiological sleep on various movement disorders. Mov Disord 1990;5(1):8-14
13. Keen-Kim D, Freimer NB. Genetics and epidemiology of Tourette's syndrome. J Child Neurol 2006;21:665-71
14. Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. Am J Psychiatry 1993;150:98-102
15. Woods DW, Piacentini J, Himle MB, Chang S. Premonitory Urge for Tics Scale (PUTS): initial psychometric results and examination of the premonitory urge phenomenon in youths with Tic disorders. J Dev Behav Pediatr 2005;26:397-403
16. Peterson BS, Leckman JF. The temporal dynamics of tics in Gilles de la Tourette syndrome. Biol Psychiatry 1998;44:1337-1348
17. Singer HS. Tourette's syndrome: from behaviour to biology. Lancet Neurol 2005;4:149-159
18. Harris K, Singer HS. Tic disorders: neural circuits, neurochemistry, and neuroimmunology. J Child Neurol 2006;21(8):678-689
19. Pulst SM, Walshe TM, Romero JA. Carbon monoxide poisoning with features of Gilles de la Tourette's syndrome. Arch Neurol 1983;40:443-444
20. Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord 2002;17:821-825
21. Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology 1990;40:999-1000
22. Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia 2000;41:862-867
23. Kurlan R, Kersun J, Behr J, et al. Carbamazepine-induced tics. Clin Neuropharmacol 1989;12:298-302
24. Bharucha KJ, Sethi KD. Tardive tourettism after exposure to neuroleptic therapy. Mov Disord 1995;10:791-793
25. Polizos P, Engelhardt DM, Hoffman SP, Waizer J. Neurological consequences of psychotropic drug withdrawal in schizophrenic children. J Autism Child Schizophr 1973;3:247-253
26. Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord 2007;22(12):1743-1750
27. Martino D, Defazio G, Giovannoni G. The PANDAS subgroup of tic disorders and childhood-onset obsessive-compulsive disorder. J Psychosom Res 2009;67(6):547-557
28. Albin RL, Koeppe RA, Bohnen NI, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology 2003;61(3):310-315
29. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997;154:1057-1062
30. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry 1978;135:585-587
31. Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders. Arch Neurol 1984;41:271-272
32. Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009;(2):CD006996
33. Jensen PS, Buitelaar J, Pandina GJ, et al. Management of psychiatric disorders in children and adolescents with atypical antipsychotics A systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007;16:104-120
34. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000;39:292-299
35. Yoo HK, Choi SH, Park S, et al. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 2007;68:1088-1093
36. Lyon GJ, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. J child Adolesc Psychopharmacol 2009;19(6):623-633
37. Murphy TK, Mutch PJ, Reid JM, et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009;19(4):441-447
38. Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008;18(5):509-515
39. Onofrj M, Paci C, D'Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000;247:443-446
40. Ho CS, Chen HJ, Chiu NC, et al. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009;108(10):788-793
41. Fountoulakis KN, Iacovides A, St Kaprinis G. Successful treatment of Tourette's disorder with amisulpride. Ann Pharmacother 2004;38(5):901
42. Tourette Syndrome Study Group. Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 2002;58:527-536
43. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067-1074
44. King A, Harris P, Fritzell J, Kurlan R. Syncope in children with Tourette's syndrome treated with guanfacine. Mov Disord 2006;21:419-420
45. Black KJ, Mink JW. Response to levodopa challenge in Tourette syndrome. Mov Disord 2000;15:1194-1198
46. Anca MH, Giladi N, Korczyn AD. Ropinirole in Gilles de la Tourette syndrome. Neurology 2004;62:1626-1627
47. Pramipexole Pilot Phase II Study in children and adolescents with tourette disorder according to DSM-IV criteria. Available from: ct2/show/NCT00558467?term= pramipexole+tourette&rank=1 [Last accessed 25 Feb 2010]
48. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009;8(9):844-856
49. Hoekstra PJ, Anderson GM, Limburg PC, et al. Neurobiology and neuroimmunology of Tourette's syndrome: an update. Cell Mol Life Sci 2004;61(7-8):886-898
50. Singer HS, Minzer K. Neurobiology of Tourette syndrome: concepts of neuroanatomical localization and neurochemical abnormalities. Brain Dev 2003;25(Suppl):S70-84
51. Steingard RJ, Goldberg M, Lee D, DeMaso DR. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 1994;33:394-399
52. Troung DD, Bressman S, Shale H, Fahn S. Clonazepam, haloperidol, and clonidine in tic disorders. South Med J 1988;81:1103-1105
53. Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a doubleblind, placebo-controlled, crossover trial. Neurology 2001;56:599-604
54. Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and Levetiracetam in Tourette syndrome. Pediatr Neurol 2009;40(6):420-425
55. Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Move Disord 2007;22:1764-1770
56. Awaad Y, Michon AM, Minarik S. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Move Disord 2005;20:714-718
57. Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010;81(1):70-73
58. Cubo E, Fernandez JaenA, Moreno C, et al. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study. Clin Ther 2008;30(1):182-189
59. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007;17(6):761-767
60. Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential Efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 2009;42(1):81-93
61. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008;165(3):335-341, quiz 409
62. Haugbol S, Pinborg LH, Regeur L, et al. Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. Int J Neuropsychopharmacol 2007;10:245-252
63. Bonnier C, Nassogne MC, Evrard P. Ketanserin treatment of Tourette's syndrome in children. Am J Psychiatry 1999;156:1122-1123
64. Toren P, Laor N, Cohen DJ, et al. Ondansetron treatment in patients with Tourette's syndrome. Int Clin Psychopharmacol 1999;14(6):373-376
65. Toren P, Weizman A, Ratner S, et al. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005;66:499-503
66. Marinelli M, Rudick CN, Hu XT, White FJ. Excitability of dopamine neurons: modulation and physiological consequences. CNS Neurol Disord Drug Targets 2006;5:79-97
67. Peterson BS, Leckman JF, Scahill L, et al. steroid hormones and CNS sexual dimorphisms modulate symptom expression in Tourette's syndrome. Psychoneuroendocrinology 1992;17(6):553-563
68. Peterson BS, Zhang H, Anderson GM, Leckman JF. Double-blind, placebo-controlled, crossover trial of an antiandrogen in the treatment of Tourette's syndrome. J Clin Psychopharmacol 1998;18(4):324-331
69. Bortolato M, Muroni A, Marrosu F. Treatment of Tourette's syndrome with finasteride. Am J Psychiatry 2007;164:1914-1915
70. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003;2:291-298
71. Romero J, Lastres-Becker I, de Miguel R, et al. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002;95:137-152
72. Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev 2009;(4):CD006565
73. Marras C, Andrews D, Sime EA, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001;56:605-610
74. Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, et al. Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord 2008;14:443-445
75. Bloch MH. Emerging treatments for Tourette's disorder. Curr Psychiatry Rep 2008;10(4):323-330
76. Orth M. Transcranial magnetic stimulation in Gilles de la Tourette syndrome. J Psychosom Res 2009;67(6):591-598
77. Transcranial Magnetic Stimulation (TMS) for Individuals With Severe Tourette's Syndrome. Available from: NCT00529308?term=tics+rTMS&rank=3 on 25 Feb 2010
78. Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome (rTMSPPCGT). Available from: clinicaltrials.gov/ct2/show/ NCT01043549?term= tics+rTMS&rank=1 on 25 Feb 2010
79. Porta M, Servello D, Sassi M, et al. Issues related to deep brain stimulation for treatment-refractory Tourette's syndrome. Eur Neurol 2009;62(5):264-273
80. Thalamic Deep Brain Stimulation for Tourette Syndrome. Available from: NCT00311909?term=dbs+tics&rank=1 on 27 Feb 2010
81. Pallidal Stimulation and Gilles de la Tourette Syndrome (STIC). Available from: NCT00478842?term=dbs+tics&rank=2 on 27 Feb 2010
82. Piacentini J, Chang S. Habit reversal training for tic disorders in children and adolescents. Behav Modif 2005;29(6):803-822
83. Wetterneck C, Woods D. An evaluation of the effectiveness of exposure and response prevention on repetitive behaviours associated with Tourette's syndrome. J Appl Behav Anal 2006;39(4):441-444
84. Deckersbach T, Rauch S, Buhlmann U, Wilhelm S. Habit reversal versus supportive psychotherapy in Tourette's disorder: a randomized controlled trial and predictors of treatment response. Behav Res Ther 2006;44(8):1079-1090
85. Goodman WK, Storch EA, Geffken GR, Murphy TK. Obsessive-compulsive disorder in Tourette syndrome 2006;21(8):704-714
86. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-632 (Pubitemid 43989810)